Covered recipient · General Payments record
KELLEY WILSON
Allopathic & Osteopathic Physicians Psychiatry & Neurology Psychiatry
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$268.69
10 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $268.69 | 10 |
By paying entity
PY2021 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | $96.09 | 4 |
| Galderma Laboratories, L.P. | $73.81 | 1 |
| GENZYME CORPORATION | $45.58 | 2 |
| Janssen Biotech, Inc. | $31.98 | 2 |
| Allergan, Inc. | $21.23 | 1 |
Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
KELLEY WILSON
NPI 1932398757 · CMS profile ID 224261
Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Psychiatry
TAMPA, FL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1932398757?year=2021&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- KELLEY WILSON, NPI 1932398757, CMS profile ID 224261. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1932398757?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). KELLEY WILSON, NPI 1932398757, CMS profile ID 224261. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1932398757?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- KELLEY WILSON, NPI 1932398757, CMS profile ID 224261, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1932398757?year=2021&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
10 matching records · $268.69 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–10 of 10.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Regeneron Healthcare Solutions, Inc. | $23.43 | 11/30/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 809637821 | CMS |
| Regeneron Healthcare Solutions, Inc. | $20.33 | 10/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 809637819 | CMS |
| GENZYME CORPORATION | $21.96 | 07/22/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 843609393 | CMS |
| Galderma Laboratories, L.P. | $73.81 | 07/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 855309807 | CMS |
| Regeneron Healthcare Solutions, Inc. | $22.09 | 06/29/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 809637817 | CMS |
| Janssen Biotech, Inc. | $17.15 | 06/22/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788837925 | CMS |
| Janssen Biotech, Inc. | $14.83 | 04/21/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788837927 | CMS |
| Regeneron Healthcare Solutions, Inc. | $30.24 | 04/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 809637815 | CMS |
| Allergan, Inc. | $21.23 | 03/24/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 792992377 | CMS |
| GENZYME CORPORATION | $23.62 | 01/12/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 843609347 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $2,698,890.20 | 111 |
| PY2024 | Principal investigator | $3,248,583.50 | 103 |
| PY2023 | Recipient | $1,039.86 | 1 |
| PY2023 | Principal investigator | $1,084,081.62 | 189 |
| PY2022 | Recipient | $1,428.00 | 1 |
| PY2022 | Principal investigator | $532,395.28 | 190 |
| PY2021 | Recipient | $1,678.03 | 1 |
| PY2021 | Principal investigator | $1,711,588.07 | 233 |
| PY2020 | Principal investigator | $1,081,919.61 | 115 |
| PY2019 | Principal investigator | $698,002.09 | 160 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
160 records in PY2019
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Allergan Inc. | $600.00 | 12/31/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY OLYMPIAN CLINICA | A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 670123423 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,500.00 | 12/30/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A Prospective, Matched-Control, Randomized, Open-Label, Flexible-Dose, Study in Subjects With Recent-Onset Schizophrenia or Schizophreniform Disorder to Compare Disease Progression and Disease Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics | No dispute reported | 06/30/2026 | 654241445 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,020.00 | 12/30/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Guselkumab for the Treatment of Subjects with Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 654241481 |
| Principal investigator 1 | AbbVie, Inc. | $225.00 | 12/26/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY, INC. | M16-045 | No dispute reported | 06/30/2026 | 647590361 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,452.00 | 12/23/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Guselkumab for the Treatment of Subjects with Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 654241479 |
| Principal investigator 1 | AbbVie, Inc. | $8,397.47 | 12/12/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY, INC. | M16-045 | No dispute reported | 06/30/2026 | 647590363 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $500.00 | 12/05/2019 | Non-covered Recipient Entity ACADEMIC ALLICANCE IN DERMATOLOGY INC | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia | No dispute reported | 06/30/2026 | 685012281 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,500.00 | 11/29/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A Prospective, Matched-Control, Randomized, Open-Label, Flexible-Dose, Study in Subjects With Recent-Onset Schizophrenia or Schizophreniform Disorder to Compare Disease Progression and Disease Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics | No dispute reported | 06/30/2026 | 654241441 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $42.00 | 11/28/2019 | Non-covered Recipient Entity ACADEMIC ALLICANCE IN DERMATOLOGY INC | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia | No dispute reported | 06/30/2026 | 685012277 |
| Principal investigator 1 | Avanir Pharmaceuticals, Inc. | $4,258.70 | 11/21/2019 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | 15-AVP-786-303 | No dispute reported | 06/30/2026 | 656018073 |
| Principal investigator 1 | Avanir Pharmaceuticals, Inc. | $14.89 | 11/14/2019 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | 15-AVP-786-303 | No dispute reported | 06/30/2026 | 656018071 |
| Principal investigator 1 | AbbVie, Inc. | $4,143.80 | 11/13/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY, INC. | M16-045 | No dispute reported | 06/30/2026 | 647590365 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,280.00 | 11/08/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A Phase 2a Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multi-center Study Investigating the Efficacy, Safety, Tolerability and Pharmacokinetics of JNJ67953964 in Subjects with Major Depressive Disorder. | No dispute reported | 06/30/2026 | 654241485 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,698.00 | 11/04/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Guselkumab for the Treatment of Subjects with Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 654241483 |
| Principal investigator 1 | Eisai Inc. | $7.50 | 10/29/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 702536245 |
| Principal investigator 1 | Eisai Inc. | $75.00 | 10/29/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 702536247 |
| Principal investigator 1 | Eisai Inc. | $1,032.00 | 10/29/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 702536249 |
| Principal investigator 1 | Eisai Inc. | $175.00 | 10/29/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 702536251 |
| Principal investigator 1 | Allergan Inc. | $225.00 | 10/22/2019 | Non-covered Recipient Entity COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP | AN OPEN LABEL, LONG TERM SAFETY STUDY OF RAPASTINEL AS AN ADJUNCTIVE THERAPY IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER MDD. | No dispute reported | 06/30/2026 | 670088235 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,473.00 | 10/18/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Guselkumab for the Treatment of Subjects with Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 654241477 |
| Principal investigator 1 | AbbVie, Inc. | $5,779.75 | 10/11/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY, INC. | M16-045 | No dispute reported | 06/30/2026 | 647590359 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $35.00 | 10/01/2019 | Non-covered Recipient Entity OLYMPIAN CLINICAL RSRCH | Adjunctive Computerized Cognitive Training (CCT) | No dispute reported | 06/30/2026 | 703922815 |
| Principal investigator 1 | Avanir Pharmaceuticals, Inc. | $2,732.57 | 09/27/2019 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | 15-AVP-786-303 | No dispute reported | 06/30/2026 | 656018069 |
| Principal investigator 1 | Allergan Inc. | $1,000.00 | 09/24/2019 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | AN OPEN LABEL, LONG TERM SAFETY STUDY OF RAPASTINEL AS AN ADJUNCTIVE THERAPY IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER MDD. | No dispute reported | 06/30/2026 | 670079627 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,271.00 | 09/23/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Guselkumab for the Treatment of Subjects with Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 654241475 |
| Principal investigator 1 | Allergan Inc. | $950.00 | 09/13/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY OLYMPIAN CLINICA | A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 670075365 |
| Principal investigator 1 | AbbVie, Inc. | $19,170.24 | 09/12/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY, INC. | M16-045 | No dispute reported | 06/30/2026 | 647590355 |
| Principal investigator 1 | AbbVie, Inc. | $13,983.12 | 09/12/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY, INC. | M16-045 | No dispute reported | 06/30/2026 | 647590357 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,853.75 | 09/05/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A Prospective, Matched-Control, Randomized, Open-Label, Flexible-Dose, Study in Subjects With Recent-Onset Schizophrenia or Schizophreniform Disorder to Compare Disease Progression and Disease Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics | No dispute reported | 06/30/2026 | 654241437 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $35.00 | 09/01/2019 | Non-covered Recipient Entity OLYMPIAN CLINICAL RSRCH | Adjunctive Computerized Cognitive Training (CCT) | No dispute reported | 06/30/2026 | 703921909 |
| Principal investigator 1 | Eisai Inc. | $3,802.00 | 08/27/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 702536227 |
| Principal investigator 1 | Allergan Inc. | $950.00 | 08/23/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY OLYMPIAN CLINICA | A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 670068945 |
| Principal investigator 1 | Allergan Inc. | $2,348.05 | 08/22/2019 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | AN OPEN LABEL, LONG TERM SAFETY STUDY OF RAPASTINEL AS AN ADJUNCTIVE THERAPY IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER MDD. | No dispute reported | 06/30/2026 | 670067831 |
| Principal investigator 1 | Avanir Pharmaceuticals, Inc. | $12,984.65 | 08/22/2019 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | 15-AVP-786-303 | No dispute reported | 06/30/2026 | 656018067 |
| Principal investigator 1 | AbbVie, Inc. | $21,675.00 | 08/20/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY, INC. | M16-045 | No dispute reported | 06/30/2026 | 647590353 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,850.00 | 08/19/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Guselkumab for the Treatment of Subjects with Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 654241473 |
| Principal investigator 1 | Eisai Inc. | $2,361.00 | 08/15/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 702536229 |
| Principal investigator 1 | Eisai Inc. | $2,533.00 | 08/15/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 702536231 |
| Principal investigator 1 | Otsuka Pharmaceutical Development & Commercialization, Inc. | $26,957.00 | 08/08/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | AN OPEN-LABEL, 52-WEEK, MULTICENTER TRIAL EVALUATING THE LONG-TERM SAFETY AND TOLERABILITY OF CENTANAFADINE SUSTAINED-RELEASE TABLETS IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER | No dispute reported | 06/30/2026 | 696054847 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $3,580.00 | 08/07/2019 | Non-covered Recipient Entity ACADEMIC ALLICANCE IN DERMATOLOGY INC | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia | No dispute reported | 06/30/2026 | 685010044 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $35.00 | 08/01/2019 | Non-covered Recipient Entity OLYMPIAN CLINICAL RSRCH | Adjunctive Computerized Cognitive Training (CCT) | No dispute reported | 06/30/2026 | 703921085 |
| Principal investigator 1 | AbbVie, Inc. | $3,349.43 | 07/30/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY, INC. | M16-045 | No dispute reported | 06/30/2026 | 647590381 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,648.75 | 07/29/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A Prospective, Matched-Control, Randomized, Open-Label, Flexible-Dose, Study in Subjects With Recent-Onset Schizophrenia or Schizophreniform Disorder to Compare Disease Progression and Disease Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics | No dispute reported | 06/30/2026 | 654241435 |
| Principal investigator 1 | AbbVie, Inc. | $500.00 | 07/22/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY, INC. | M16-045 | No dispute reported | 06/30/2026 | 647590383 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $13,340.00 | 07/22/2019 | Non-covered Recipient Entity Academic Alliance in Dermatology | Adjunctive Computerized Cognitive Training CCT | No dispute reported | 06/30/2026 | 704143347 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,469.00 | 07/22/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Guselkumab for the Treatment of Subjects with Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 654241471 |
| Principal investigator 1 | Janssen Research & Development, LLC | $520.00 | 07/18/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A Phase 2a Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multi-center Study Investigating the Efficacy, Safety, Tolerability and Pharmacokinetics of JNJ67953964 in Subjects with Major Depressive Disorder. | No dispute reported | 06/30/2026 | 654241469 |
| Principal investigator 1 | Allergan Inc. | $1,000.00 | 07/11/2019 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY OF RAPASTINEL AS ADJUNCTIVE THERAPY IN THE PREVENTION OF RELAPSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 670056447 |
| Principal investigator 1 | Allergan Inc. | $750.00 | 07/09/2019 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 670055815 |
| Principal investigator 1 | Alkermes, Inc. | $1,391.40 | 07/08/2019 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | A Phase 3 Study to Evaluate Weight Gain of ALKS 3831 Compared to OLANZAPINE in Adults with Schizophrenia | No dispute reported | 06/30/2026 | 653533199 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $35.00 | 07/01/2019 | Non-covered Recipient Entity OLYMPIAN CLINICAL RSRCH | Adjunctive Computerized Cognitive Training (CCT) | No dispute reported | 06/30/2026 | 703917773 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,018.00 | 06/28/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Guselkumab for the Treatment of Subjects with Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 654241465 |
| Principal investigator 1 | AbbVie, Inc. | $9,765.17 | 06/27/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY, INC. | M16-045 | No dispute reported | 06/30/2026 | 647590379 |
| Principal investigator 1 | Eisai Inc. | $75.00 | 06/27/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 702536235 |
| Principal investigator 1 | Eli Lilly and Company | $2,500.00 | 06/11/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY COMPARING THE EFFICACY AND SAFETY OF IXEKIZUMAB VERSUS PLACEBO IN PATIENTS WITH MODERATE-TO-SEVERE GENITAL PSORIASIS | No dispute reported | 06/30/2026 | 654287317 |
| Principal investigator 1 | Allergan Inc. | $4,200.00 | 06/06/2019 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY OF RAPASTINEL AS ADJUNCTIVE THERAPY IN THE PREVENTION OF RELAPSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 670050717 |
| Principal investigator 1 | Neurocrine Biosciences, Inc. | $125.00 | 06/06/2019 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | OPEN-LABEL SAFETY AND TOLERABILITY STUDY OF NBI-98854 FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME | No dispute reported | 06/30/2026 | 686566369 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $35.00 | 06/01/2019 | Non-covered Recipient Entity OLYMPIAN CLINICAL RSRCH | Adjunctive Computerized Cognitive Training (CCT) | No dispute reported | 06/30/2026 | 703912403 |
| Principal investigator 1 | Allergan Inc. | $2,000.00 | 05/30/2019 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 670049717 |
| Principal investigator 1 | Eisai Inc. | $3,944.00 | 05/30/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 702536237 |
| Principal investigator 1 | AbbVie, Inc. | $3,092.57 | 05/29/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY, INC. | M16-045 | No dispute reported | 06/30/2026 | 647590375 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $500.00 | 05/29/2019 | Non-covered Recipient Entity ACADEMIC ALLICANCE IN DERMATOLOGY INC | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia | No dispute reported | 06/30/2026 | 685007475 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,081.75 | 05/27/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A Prospective, Matched-Control, Randomized, Open-Label, Flexible-Dose, Study in Subjects With Recent-Onset Schizophrenia or Schizophreniform Disorder to Compare Disease Progression and Disease Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics | No dispute reported | 06/30/2026 | 654241433 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,635.00 | 05/24/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Guselkumab for the Treatment of Subjects with Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 654241467 |
| Principal investigator 1 | Avanir Pharmaceuticals, Inc. | $2,500.00 | 05/23/2019 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | 15-AVP-786-301 | No dispute reported | 06/30/2026 | 656018065 |
| Principal investigator 1 | Allergan Inc. | $500.00 | 05/21/2019 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 670047257 |
| Principal investigator 1 | AbbVie, Inc. | $150.00 | 05/15/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY, INC. | M16-045 | No dispute reported | 06/30/2026 | 647590377 |
| Principal investigator 1 | Eisai Inc. | $75.00 | 05/07/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 702536233 |
| Principal investigator 1 | Neurocrine Biosciences, Inc. | $203.00 | 05/02/2019 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | OPEN-LABEL SAFETY AND TOLERABILITY STUDY OF NBI-98854 FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME | No dispute reported | 06/30/2026 | 686565849 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $35.00 | 05/01/2019 | Non-covered Recipient Entity OLYMPIAN CLINICAL RSRCH | Adjunctive Computerized Cognitive Training (CCT) | No dispute reported | 06/30/2026 | 703912249 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $80.00 | 05/01/2019 | Non-covered Recipient Entity OLYMPIAN CLINICAL RSRCH | Adjunctive Computerized Cognitive Training (CCT) | No dispute reported | 06/30/2026 | 703912325 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $12.50 | 05/01/2019 | Non-covered Recipient Entity OLYMPIAN CLINICAL RSRCH | Adjunctive Computerized Cognitive Training (CCT) | No dispute reported | 06/30/2026 | 703912335 |
| Principal investigator 1 | AbbVie, Inc. | $2,910.81 | 04/29/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY, INC. | M16-045 | No dispute reported | 06/30/2026 | 647590373 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,932.50 | 04/26/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A Prospective, Matched-Control, Randomized, Open-Label, Flexible-Dose, Study in Subjects With Recent-Onset Schizophrenia or Schizophreniform Disorder to Compare Disease Progression and Disease Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics | No dispute reported | 06/30/2026 | 654241429 |
| Principal investigator 1 | Janssen Research & Development, LLC | $706.00 | 04/26/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A Phase 2a Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multi-center Study Investigating the Efficacy, Safety, Tolerability and Pharmacokinetics of JNJ67953964 in Subjects with Major Depressive Disorder. | No dispute reported | 06/30/2026 | 654241463 |
| Principal investigator 1 | Avanir Pharmaceuticals, Inc. | $1,306.25 | 04/25/2019 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | 15-AVP-786-301 | No dispute reported | 06/30/2026 | 656018059 |
| Principal investigator 1 | Avanir Pharmaceuticals, Inc. | $6,275.00 | 04/25/2019 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | 15-AVP-786-301 | No dispute reported | 06/30/2026 | 656018061 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $950.98 | 04/25/2019 | Non-covered Recipient Entity OLYMPIAN CLINICAL RSRCH | Adjunctive Computerized Cognitive Training (CCT) | No dispute reported | 06/30/2026 | 703912363 |
| Principal investigator 1 | Eli Lilly and Company | $265.10 | 04/25/2019 | Non-covered Recipient Entity PRES AND DIR GEORGETOWN COLLEGE FOR GRGTWN UNIV | A 24-WEEK MULTICENTER, RANDOMIZED, BLINDED, PARALLEL-GROUP STUDY COMPARING THE EFFICACY AND SAFETY OF IXEKIZUMAB TO GUSELKUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS | No dispute reported | 06/30/2026 | 654290361 |
| Principal investigator 1 | Neurocrine Biosciences, Inc. | $1,000.00 | 04/25/2019 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | SAFETY, TOLERABILITY, AND EFFICACY OF NBI-98854 FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME | No dispute reported | 06/30/2026 | 686565743 |
| Principal investigator 1 | Otsuka Pharmaceutical Development & Commercialization, Inc. | $65,504.45 | 04/25/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED, PARALLEL-GROUP TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CENTANAFADINE SUSTAINED-RELEASE TABLETS IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER TRIAL 405-201-00014 | No dispute reported | 06/30/2026 | 696054248 |
| Principal investigator 1 | Janssen Research & Development, LLC | $19,485.00 | 04/22/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Guselkumab for the Treatment of Subjects with Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 654241461 |
| Principal investigator 1 | Neurocrine Biosciences, Inc. | $6,874.51 | 04/11/2019 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | SAFETY, TOLERABILITY, AND EFFICACY OF NBI-98854 FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME | No dispute reported | 06/30/2026 | 686565707 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,239.77 | 04/10/2019 | Non-covered Recipient Entity OLYMPIAN CLINICAL RSRCH | Adjunctive Computerized Cognitive Training (CCT) | No dispute reported | 06/30/2026 | 703925721 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,234.43 | 04/08/2019 | Non-covered Recipient Entity OLYMPIAN CLINICAL RSRCH | Adjunctive Computerized Cognitive Training (CCT) | No dispute reported | 06/30/2026 | 703925719 |
| Principal investigator 1 | Janssen Research & Development, LLC | $133.75 | 04/08/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A Prospective, Matched-Control, Randomized, Open-Label, Flexible-Dose, Study in Subjects With Recent-Onset Schizophrenia or Schizophreniform Disorder to Compare Disease Progression and Disease Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics | No dispute reported | 06/30/2026 | 654241431 |
| Principal investigator 1 | Eisai Inc. | $2,179.00 | 04/04/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 702536239 |
| Principal investigator 1 | Eisai Inc. | $1,421.00 | 04/04/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 702536241 |
| Principal investigator 1 | Eisai Inc. | $1,032.00 | 04/04/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 702536243 |
| Principal investigator 1 | Neurocrine Biosciences, Inc. | $2,002.55 | 04/04/2019 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | OPEN-LABEL SAFETY AND TOLERABILITY STUDY OF NBI-98854 FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME | No dispute reported | 06/30/2026 | 686565415 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $905.86 | 04/02/2019 | Non-covered Recipient Entity OLYMPIAN CLINICAL RSRCH | BI 425809 Adjunctive Computerized Cognitive Training (CCT) | No dispute reported | 06/30/2026 | 708445811 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $991.56 | 04/02/2019 | Non-covered Recipient Entity OLYMPIAN CLINICAL RSRCH | Adjunctive Computerized Cognitive Training CCT | No dispute reported | 06/30/2026 | 704143501 |
| Principal investigator 1 | AbbVie, Inc. | $2,293.78 | 03/29/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY, INC. | M16-045 | No dispute reported | 06/30/2026 | 647590371 |
| Principal investigator 1 | Alkermes, Inc. | $500.00 | 03/28/2019 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | A Phase 3 Study to Evaluate Weight Gain of ALKS 3831 Compared to OLANZAPINE in Adults with Schizophrenia | No dispute reported | 06/30/2026 | 653533197 |
| Principal investigator 1 | Neurocrine Biosciences, Inc. | $4,193.73 | 03/28/2019 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | OPEN-LABEL SAFETY AND TOLERABILITY STUDY OF NBI-98854 FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME | No dispute reported | 06/30/2026 | 686565305 |
| Principal investigator 1 | Eli Lilly and Company | $11,284.00 | 03/18/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A 24-WEEK MULTICENTER, RANDOMIZED, BLINDED, PARALLEL-GROUP STUDY COMPARING THE EFFICACY AND SAFETY OF IXEKIZUMAB TO GUSELKUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS | No dispute reported | 06/30/2026 | 654287199 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,356.00 | 03/18/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Guselkumab for the Treatment of Subjects with Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 654241455 |
| Principal investigator 1 | Allergan Inc. | $4,450.00 | 03/14/2019 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY OF RAPASTINEL AS ADJUNCTIVE THERAPY IN THE PREVENTION OF RELAPSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 670030483 |
| Principal investigator 1 | Eisai Inc. | $1,413.00 | 03/12/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 702536191 |
| Principal investigator 1 | Eisai Inc. | $811.00 | 03/12/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 702536193 |
| Principal investigator 1 | Eisai Inc. | $1,413.00 | 03/12/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 702536195 |
| Principal investigator 1 | Eisai Inc. | $811.00 | 03/12/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 702536197 |
| Principal investigator 1 | Eisai Inc. | $1,570.00 | 03/12/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 702536199 |
| Principal investigator 1 | Eisai Inc. | $75.00 | 03/12/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 702536201 |
| Principal investigator 1 | Eisai Inc. | $2,361.00 | 03/12/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 702536203 |
| Principal investigator 1 | Eisai Inc. | $3,802.00 | 03/12/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 702536205 |
| Principal investigator 1 | Eisai Inc. | $3,802.00 | 03/12/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 702536207 |
| Principal investigator 1 | Eisai Inc. | $1,896.00 | 03/12/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 702536209 |
| Principal investigator 1 | Eisai Inc. | $1,570.00 | 03/12/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 702536211 |
| Principal investigator 1 | Eisai Inc. | $75.00 | 03/12/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 702536213 |
| Principal investigator 1 | Eisai Inc. | $516.00 | 03/12/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 702536215 |
| Principal investigator 1 | Eisai Inc. | $75.00 | 03/12/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 702536217 |
| Principal investigator 1 | Eisai Inc. | $329.00 | 03/12/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 702536219 |
| Principal investigator 1 | Eisai Inc. | $75.00 | 03/12/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 702536221 |
| Principal investigator 1 | Eisai Inc. | $329.00 | 03/12/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 702536223 |
| Principal investigator 1 | Eisai Inc. | $75.00 | 03/12/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 702536225 |
| Principal investigator 1 | Eli Lilly and Company | $7,728.00 | 03/07/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A 24-MONTH, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY, SAFETY, TOLERABILITY, BIOMARKER, AND PHARMACOKINETIC STUDY OF AZD3293 IN EARLY ALZHEIMERS DISEASE -THE AMARANTH STUDY | No dispute reported | 06/30/2026 | 654287281 |
| Principal investigator 1 | Otsuka Pharmaceutical Development & Commercialization, Inc. | $6,945.36 | 03/07/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND ACTIVE-CONTROLLED TRIAL OF BREXPIPRAZOLE 1 - 3 MGDAY AS MONOTHERAPY OR AS COMBINATION THERAPY IN THE TREATMENT OF ADULTS WITH POST-TRAUMATIC STRESS DISORDER | No dispute reported | 06/30/2026 | 696053541 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,110.00 | 03/04/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A Prospective, Matched-Control, Randomized, Open-Label, Flexible-Dose, Study in Subjects With Recent-Onset Schizophrenia or Schizophreniform Disorder to Compare Disease Progression and Disease Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics | No dispute reported | 06/30/2026 | 654241425 |
| Principal investigator 1 | AbbVie, Inc. | $15,726.17 | 02/28/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY, INC. | M16-045 | No dispute reported | 06/30/2026 | 647590369 |
| Principal investigator 1 | Eli Lilly and Company | $22.36 | 02/21/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A 24-WEEK MULTICENTER, RANDOMIZED, BLINDED, PARALLEL-GROUP STUDY COMPARING THE EFFICACY AND SAFETY OF IXEKIZUMAB TO GUSELKUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS | No dispute reported | 06/30/2026 | 654287201 |
| Principal investigator 1 | Neurocrine Biosciences, Inc. | $203.00 | 02/21/2019 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | SAFETY, TOLERABILITY, AND EFFICACY OF NBI-98854 FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME | No dispute reported | 06/30/2026 | 686564663 |
| Principal investigator 1 | AbbVie, Inc. | $5,000.00 | 02/19/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY, INC. | M16-045 | No dispute reported | 06/30/2026 | 647590367 |
| Principal investigator 1 | Janssen Research & Development, LLC | $11,701.00 | 02/18/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Guselkumab for the Treatment of Subjects with Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 654241453 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,000.00 | 02/15/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A Phase 2a Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multi-center Study Investigating the Efficacy, Safety, Tolerability and Pharmacokinetics of JNJ67953964 in Subjects with Major Depressive Disorder. | No dispute reported | 06/30/2026 | 654241447 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,554.00 | 02/15/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A Double-blind, Randomized, Active-controlled, Parallel-group Study of Paliperidone Palmitate 6-Month Formulation | No dispute reported | 06/30/2026 | 654241449 |
| Principal investigator 1 | Neurocrine Biosciences, Inc. | $5,701.10 | 02/07/2019 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | OPEN-LABEL SAFETY AND TOLERABILITY STUDY OF NBI-98854 FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME | No dispute reported | 06/30/2026 | 686564435 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $3,285.00 | 02/06/2019 | Non-covered Recipient Entity ACADEMIC ALLICANCE IN DERMATOLOGY INC | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia | No dispute reported | 06/30/2026 | 685006307 |
| Principal investigator 1 | Avanir Pharmaceuticals, Inc. | $2,031.25 | 01/31/2019 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | 15-AVP-786-301 | No dispute reported | 06/30/2026 | 656018057 |
| Principal investigator 1 | Neurocrine Biosciences, Inc. | $5.18 | 01/31/2019 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | OPEN-LABEL SAFETY AND TOLERABILITY STUDY OF NBI-98854 FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME | No dispute reported | 06/30/2026 | 686563999 |
| Principal investigator 1 | Neurocrine Biosciences, Inc. | $5.18 | 01/31/2019 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | SAFETY, TOLERABILITY, AND EFFICACY OF NBI-98854 FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME | No dispute reported | 06/30/2026 | 686564043 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,492.50 | 01/25/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A Prospective, Matched-Control, Randomized, Open-Label, Flexible-Dose, Study in Subjects With Recent-Onset Schizophrenia or Schizophreniform Disorder to Compare Disease Progression and Disease Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics | No dispute reported | 06/30/2026 | 654241427 |
| Principal investigator 1 | Eisai Inc. | $1,413.00 | 01/24/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 702536167 |
| Principal investigator 1 | Eisai Inc. | $75.00 | 01/24/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 702536169 |
| Principal investigator 1 | Eisai Inc. | $3,802.00 | 01/24/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 702536171 |
| Principal investigator 1 | Eisai Inc. | $2,794.00 | 01/24/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 702536173 |
| Principal investigator 1 | Eisai Inc. | $811.00 | 01/24/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 702536175 |
| Principal investigator 1 | Eisai Inc. | $1,570.00 | 01/24/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 702536177 |
| Principal investigator 1 | Eisai Inc. | $75.00 | 01/24/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 702536179 |
| Principal investigator 1 | Eisai Inc. | $516.00 | 01/24/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 702536181 |
| Principal investigator 1 | Eisai Inc. | $75.00 | 01/24/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 702536183 |
| Principal investigator 1 | Eisai Inc. | $329.00 | 01/24/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 702536185 |
| Principal investigator 1 | Eisai Inc. | $75.00 | 01/24/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 702536187 |
| Principal investigator 1 | Eisai Inc. | $2,361.00 | 01/24/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 702536189 |
| Principal investigator 1 | Otsuka Pharmaceutical Development & Commercialization, Inc. | $2,328.57 | 01/22/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF BREXPIPRAZOLE AS ADJUNCTIVE THERAPY IN THE MAINTENANCE TREATMENT OF ADULTS WITH MAJOR DEPRESSIVE DISORDER. | No dispute reported | 06/30/2026 | 696053269 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,407.00 | 01/21/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Guselkumab for the Treatment of Subjects with Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 654241457 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,650.00 | 01/21/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Guselkumab for the Treatment of Subjects with Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 654241459 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $79,080.53 | 01/14/2019 | Non-covered Recipient Entity Olympian Clinical Research - South Tampa Office | A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects with Moderate to Severe Psoriasis | No dispute reported | 06/30/2026 | 639758701 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,595.00 | 01/14/2019 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A Double-blind, Randomized, Active-controlled, Parallel-group Study of Paliperidone Palmitate 6-Month Formulation | No dispute reported | 06/30/2026 | 654241451 |
| Principal investigator 1 | Avanir Pharmaceuticals, Inc. | $18.17 | 01/10/2019 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | 15-AVP-786-301 | No dispute reported | 06/30/2026 | 656018053 |
| Principal investigator 1 | Avanir Pharmaceuticals, Inc. | $6,525.16 | 01/10/2019 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | 15-AVP-786-303 | No dispute reported | 06/30/2026 | 656018055 |
| Principal investigator 1 | Neurocrine Biosciences, Inc. | $3,863.61 | 01/10/2019 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | OPEN-LABEL SAFETY AND TOLERABILITY STUDY OF NBI-98854 FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME | No dispute reported | 06/30/2026 | 686563573 |
| Principal investigator 1 | Neurocrine Biosciences, Inc. | $46.00 | 01/03/2019 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | OPEN-LABEL SAFETY AND TOLERABILITY STUDY OF NBI-98854 FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME | No dispute reported | 06/30/2026 | 686562749 |
| Principal investigator 1 | Neurocrine Biosciences, Inc. | $46.00 | 01/03/2019 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | SAFETY, TOLERABILITY, AND EFFICACY OF NBI-98854 FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME | No dispute reported | 06/30/2026 | 686563061 |
| Principal investigator 1 | Neurocrine Biosciences, Inc. | $23.50 | 01/03/2019 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | OPEN-LABEL SAFETY AND TOLERABILITY STUDY OF NBI-98854 FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME | No dispute reported | 06/30/2026 | 686563095 |
| Principal investigator 1 | Neurocrine Biosciences, Inc. | $2.93 | 01/03/2019 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | OPEN-LABEL SAFETY AND TOLERABILITY STUDY OF NBI-98854 FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME | No dispute reported | 06/30/2026 | 686563113 |
| Principal investigator 1 | Neurocrine Biosciences, Inc. | $92.00 | 01/03/2019 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | OPEN-LABEL SAFETY AND TOLERABILITY STUDY OF NBI-98854 FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME | No dispute reported | 06/30/2026 | 686563177 |
| Principal investigator 1 | Neurocrine Biosciences, Inc. | $92.00 | 01/03/2019 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | SAFETY, TOLERABILITY, AND EFFICACY OF NBI-98854 FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME | No dispute reported | 06/30/2026 | 686563217 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $4,921.88 | 01/03/2019 | Non-covered Recipient Entity ACADEMIC ALLICANCE IN DERMATOLOGY INC | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia | No dispute reported | 06/30/2026 | 685006305 |
| Principal investigator 1 | Biogen, Inc. | $81,441.55 | 01/02/2019 | Non-covered Recipient Entity Academic Alliance In Dermatology | Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 675311109 |